Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mg

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sleep Apnea, Obstructive

Conditions

Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders

Trial Timeline

Jan 6, 2021 → Feb 10, 2022

About Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mg

Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mg is a phase 1 stage product being developed by Eisai for Sleep Apnea, Obstructive. The current trial status is completed. This product is registered under clinical trial identifier NCT04647383. Target conditions include Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders.

What happened to similar drugs?

20 of 20 similar drugs in Sleep Apnea, Obstructive were approved

Approved (20) Terminated (2) Active (0)
Zolpidem MR + EstazolamAstellas PharmaApproved
Zolpidem MR + Zolpidem IRAstellas PharmaApproved
Lemborexant + PlaceboEisaiApproved
Eszopiclone + Placebo controlSumitomo PharmaApproved
Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved
Lunesta + Placebo controlSumitomo PharmaApproved
LunestaSumitomo PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04647383Phase 1Completed

Competing Products

20 competing products in Sleep Apnea, Obstructive

See all competitors